The Diabetes Drug Behind the “33% Higher Heart Risk” Headline
The drug is rosiglitazone (brand name Avandia), an older type 2 diabetes medicine in the thiazolidinedione class.
The headline is based on a large analysis of more than 130 clinical trials involving over 48,000 patients. Researchers found that rosiglitazone was associated with a 33% higher risk of major cardiovascular events compared with control treatments. The events included heart attack, heart failure, and cardiovascular death. (ScienceDaily)
⚠️ But there are important details
- The 33% figure is a relative increase, not a 33-percentage-point increase in someone’s personal risk.
- Among patients for whom individual-level data were available, 274 of 11,837 taking rosiglitazone experienced a major cardiovascular event versus 219 of 9,319 in control groups. (Knowridge Science Report)
- The study was published in 2020, so calling it a “massive new study” today is misleading. (ScienceDaily)
- Rosiglitazone’s cardiovascular safety has been controversial for years, and its use has been restricted in various jurisdictions.
🩺 Should someone taking rosiglitazone stop?
No—not without speaking to their prescriber. Suddenly stopping diabetes medication can cause blood glucose to rise.
If you’re currently taking rosiglitazone, particularly if you have heart failure, swelling, shortness of breath, or unexplained rapid weight gain, contact your doctor promptly to discuss whether it remains appropriate.
Bottom line: The underlying concern is legitimate, but the viral headline makes an older study sound new and makes the “33%” figure sound more alarming than it means. The medication involved is rosiglitazone, not common diabetes drugs such as metformin, and you shouldn’t stop a prescribed diabetes medicine based on this headline alone.
